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Tobin and colleagues show that both inhibition and excessive production of the inflammatorymedi-
ator TNFa impact the pathogenesis of tuberculosis (TB) and the response to therapy. Identifying a
critical role for the genetically determined balance between pro- and anti-inflammatory eicosanoids
in regulating TNFa levels provides a roadmap to tailored TB treatment based on host genotype.Mycobacterium tuberculosis (Mtb) has
been our unwelcome companion for
millennia, using humans to ‘‘walk’’ out of
Africa, ‘‘sail’’ out of Europe and ‘‘canoe’’
across North America. In order to infect
an estimated one-third of theworld’s pop-
ulation and cause 8.1 million new cases of
active TB annually (World Health Organi-
zation, 2011), Mtb must withstand and
exploit host immune responses to ensure
its survival and transmission. In turn, the
human immune response has been cali-
brated to optimize survival in the face of
this intracellular threat, as exemplified by
the immune control and absence of
pathology that characterize latent TB
infection. Infection develops into disease
due to bacterial dissemination resulting
from inadequate protective immunity,
whereas tissue pathology is caused by
an overly vigorous yet ineffective host
response. Identifying pathways that regu-
late and potentially dissociate protection
from pathology will aid rational develop-
ment of new interventions for treatmentand vaccination. In this issue of Cell,
Tobin and colleagues dissect a pivotal
genetic balance that maintains the host
between the two extremes of failed immu-
nity and damaging hyperimmunity (Tobin
et al., 2012).
The inhibition ofmacrophage apoptosis
and the concomitant induction of necrosis
is currently emerging as a pathway that is
important for Mtb virulence, allowing for
bacterial spread between cells prior to
the induction of an adaptive immune
response. In contrast, avirulent mycobac-
teria induce macrophage apoptosis, re-
sulting in prompt development of a
protective immune response. Converging
results from different labs have revealed
that the arachidonic acid metabolites,
eicosanoids, lipoxins, and leukotrienes
influence cell death patterns following
mycobacterial infection (Behr et al., 2010).
Lipoxin A4 (LXA4), produced through the
action of lipoxygenase enzyme, acts as
an anti-inflammatory mediator of myco-
bacterial-induced necrosis of infectedmacrophages; its key role is evidenced by
the greater resistance of LXA4-deficient
5-lipoxygense knockout (Alox5/) mice
to Mtb infection (Behar et al., 2011; Chen
et al., 2008; Divangahi et al., 2010).
Studying the natural host-pathogen
pair ofM. marinum in zebrafish, the Ram-
akrishnan laboratory previously reported
on the susceptibility to infection of mutant
fish lacking the Leukotriene A4 (LTA4)
hydrolase enzyme (Tobin et al., 2010),
responsible for converting LTA4 to proin-
flammatory Leukotriene B4 (LTB4). This
hypersusceptibility was due to increased
LXA4 levels, which resulted in decreased
transcription of TNFa and the promotion
of an anti-inflammatory environment.
Interestingly, humans heterozygous for
SNPs in the Leukotriene A4 hydrolase
(lta4h) gene were relatively protected
against tuberculosis in comparison to
either homozygote genotype. In the
current report, Tobin and colleagues
investigate the mechanisms underlying
heterozygote advantage in the eicosanoid, February 3, 2012 ª2012 Elsevier Inc. 389
Figure 1. Two Sides of TNFa
Mycobacterium tuberculosis enters and exits the lung. In most cases, infection is contained in the thorax,
resulting in either asymptomatic latent infection (in90%) or pulmonary TB (in10%). In some cases, host
containment of bacteria is compromised, and bacteria disseminate outside the thorax to distant sites,
including the meninges (Tuberculous meningitis). In a host with genetically determined high expression of
LTA4 Hydrolase (LTA4H) enzyme (TT homozygote, left) or deficient in LTA4H (CC homozygote, right),
excess proinflammatory LTB4 (left) and anti-inflammatory LXA4 (right) lead to an excess or reduced levels
of TNFa, respectively. Despite the polar opposites of a failed immune response in the case of reduced
TNFa (right) and an exuberant inflammatory response with excessive TNFa (left), a similar outcome of
macrophage necrosis and bacterial growth ensues. Immunomodulatory pharmacotherapy with dexa-
methasone to dampen the excessive inflammation reduces disease severity only in TT homozygous
(LTA4H-high) individuals and potentially has an adverse effect in CC homozygous individuals. Further
studies should provide insight into how other factors and processes, such as, for example, mycobacterial
lineage and the adaptive immune response, affect the TNFa balance maintained by the host eicosanoid
pathway.pathway (Tobin et al., 2012). Using lta4h
RNA injections into one-cell embryos
and lta4h antisense oligonucleotide, they390 Cell 148, February 3, 2012 ª2012 Elseviecreated LTA4H-high and LTA4H-low
animals. The LTA4H-low phenotype was
characterized by excess anti-inflamma-r Inc.tory LXA4 and TNFa deficiency, whereas
the LTAH4-high phenotype had increased
proinflammatory LTB4 and excess TNFa.
Remarkably, both phenotypes suc-
cumbed to M. marinum infection, with
similar increases in bacterial burden.
This susceptibility was reversed following
recombinant TNFa administration and
TNFa blockade in the anti-inflammatory
(LTA4H-low) and proinflammatory (LTA4H-
high) fish, respectively. Furthermore, phar-
macologic inhibition of lipoxins reduced
the infection burden of LTA4H-low
animals, whereas pharmacologic sup-
pression of inflammation (with the gluco-
corticoid dexamethasone or aspirin)
reduced the infection burden of LTA4H-
high animals; all effects were mediated
by TNFa, with modest changes deter-
mining the outcomes of infection.
The marked inflammatory pathology
and lymphocyte infiltration in TB menin-
gitis (TBM) have stimulated clinical trials
of immunosuppressive therapy aimed at
dampening overexuberant inflammation
in these patients suffering themost severe
form of TB (Thwaites et al., 2004). How-
ever, the response to treatment with
dexamethasone, on aggregate, has been
at best modest (Prasad and Singh,
2008). Might such ambiguous trial results
be explained by the dichotomous LTA4H
genotype-dependent action of dexa-
methasone? To investigate this, the
authors identified a functional SNP in the
promoter region of the lta4h gene that
influences mRNA transcription. Next, by
stratifying TBM patients from a historic
randomized trial by lta4h genotype, they
revealed both different outcomes of
disease and starkly different responses
to dexamethasone. Overall, heterozy-
gotes fared best. Among patients not
treated with dexamethasone, the proin-
flammatory homozygous (TT) LTA4H-
genotype had the worst outcome;
however, the survival benefit of dexa-
methasone was greatest for this geno-
type. Conversely, dexamethasone may
have worsened outcome in patients with
the anti-inflammatory homozygous (CC)
LTA4H-genotype. The elegant translation
of the zebrafish findings to human thera-
peutic efficacy has important practical
implications for clinical management of
TB as well as potentially far-reaching
evolutionary implications for host hetero-
zygote advantage in infectious diseases.
Taken together with the authors’
previous findings that heterozygosity in
the lta4h locus is associated with resis-
tance to TB and multibacillary leprosy
(Tobin et al., 2010), the present study
makes a strong case for heterozygote
advantage in mycobacterial disease, with
balancing selectionmaintaining allelic vari-
ation in the eicosanoid pathway to modu-
late balanced TNFa-mediated responses
to infection. Because resistance to TB
involves pathways that are important for
host responses to other diseases, investi-
gating theeicosanoidpathway in infections
with other intracellular pathogens may
prove fruitful.
Given that genotype determined out-
come of TBM, should not host phenotype
also be predictive? For example, can clin-
ical outcome or response to dexametha-
sone be stratified by TNFa or eicosanoid
levels in serum or cerebrospinal fluid?
How do TNFa levels change in response
to dexamethasone in TBM patients of the
homozygous (TT) genotype? Unfortu-
nately, these questions cannot be ad-
dressed in this retrospective analysis of
a clinical trial from almost a decade ago.
These and other analytes should be
measured prospectively in future clinical
trials of TBM and other forms of TB to
define the mechanism of the observed
genetic effects; if it is the same as in zebra-
fish, then these could prove to be useful
biomarkers to individualize therapy.
The consistency of zebrafish findings
with data from human studies provides
compelling evidence for the validity of
this experimental model. However, when
defining the relative importance of this
versus other pathways for humans with
TB, the effect of the more developed
mammalian adaptive immune system
may be critical, especially given that acti-
vated lymphocytes are a predominant
source of TNFa. The eicosanoid/prosta-noid pathway influences the development
of cellular immunity in themurinemodel of
TB (Divangahi et al., 2010), but how the
lta4h gene affects adaptive immunity in
humans remains to be investigated.
Furthermore, dexamethasone has pleio-
tropic immunosuppressive effects en-
compassing both innate and adaptive
immunity through transactivation of anti-
inflammatory genes and transrepression
of proinflammatory proteins. Whether
the therapeutic effects of dexamethasone
are specifically mediated via the eicosa-
noid pathway and TNFa in humans will
thus require further investigation, as will
assaying the effects of drugs like aspirin
and anti-TNFa agents. Other questions
that now need to be addressed include
the role of these immune processes
through time (progression from infection
to disease), over space (different
anatomic sites of TB disease), and across
species (when comparing hosts with
different immune systems). Can pharma-
cologic immune-modulation favor control
of infection with minimal host pathology
across different forms of TB, and if so,
can host genetics predict responsive-
ness? How do other key factors, such
as, for example, adaptive immunity,
mycobacterial lineage, and HIV, impact
the TNFa balance maintained by the
host eicosanoid pathway and suscepti-
bility to severe TB (Figure 1)?
Regardless of these questions, by es-
tablishing the pharmacogenomic basis
of immunomodulatory therapy, Tobin
et al. herald a new era of personalized
medicine in TB. The next step toward in-
forming clinical practice might therefore
be a genotype-stratified trial to assess
treatment outcome of dexamethasone
and/or aspirin in lta4h TT homozygote
TB patients compared to standard treat-
ment without immunomodulation in the
other two genotypes.Cell 148This latest contribution by the Ramak-
rishnan group conceptually extends the
one-dimensional paradigm of suscepti-
bility to mycobacteria. It suggests instead
that distinct routes toward optimal
immunity depend critically on where one
starts, a message that may also inform
the quest for a new TB vaccine. These
data present a cogent rebuttal to George
Bernard Shaw’s century-old advice from
his play The Doctor’s Dilemma: ‘‘There is
at bottom only one genuinely scientific
treatment for all diseases, and that is to
stimulate the phagocytes.’’ In light of the
present findings, the genuinely scientific
solution to the TB doctor’s dilemma may
become: ‘‘Genotype the phagocyte, then
choose the treatment.’’
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